HENT1 biomarker utilization for enhancing cancer drug development
Utilize the HENT1 biomarker to improve drug efficacy and combat resistance in cancer treatment by enhancing therapeutic delivery to malignant cells, particularly pancreatic cancer.
Overview
Utilizing the HENT1 biomarker presents a promising approach to advancing cancer treatment by enhancing the delivery and efficacy of therapeutic agents. HENT1, a transmembrane protein, facilitates the transport of nucleosides such as gemcitabine, a key chemotherapy drug. By targeting the HENT1 pathway, it is possible to improve drug uptake, reduce resistance, and ultimately enhance treatment outcomes, especially in pancreatic ductal adenocarcinoma (PDAC).
Technical specifications
Key features:
- HENT1 biomarker (10D7G2): Commercial-grade biomarker available for integration into research and clinical trials.
- Therapeutic targeting: Enhances delivery of nucleoside analogs to cancer cells, potentially improving outcomes in PDAC patients.
- Resistance mitigation: Addresses common drug resistance mechanisms in cancer by improving drug uptake and reducing efflux.
- Clinical application: Exploration of HENT1 as a predictive biomarker for new drugs in PDAC, beyond gemcitabine.
Technology readiness level
This solution is at Technology Readiness Level 9, indicating it is fully developed and commercially available. Partnerships are sought to incorporate the HENT1 biomarker in research or clinical trials to improve survival rates in PDAC patients.
About DueNorth Biodev
DueNorth BioDev provides guidance and support for patients navigating cancer screening, diagnosis confirmation, and clinical trial options. The company focuses on addressing challenges in the healthcare system, such as the difficulty patients face in locating appropriate clinical trials outside of their own institutions and the high rate of cancer misdiagnosis. By providing information and resources, they aim to help patients better understand their screening results and identify potential treatment paths when standard options are unavailable or ineffective. Their services are designed to assist individuals who may feel unsupported or overwhelmed by complex medical language and fragmented clinical trial information. Through these offerings, DueNorth BioDev acts as a resource for those seeking greater clarity and proactive management of their cancer care journey, emphasizing the importance of timely and accurate diagnosis as well as access to promising new treatment opportunities.
delivered to your inbox.